肺癌演变中的范式:诊断、管理与放射性药物的最新趋势
本文为综述,覆盖肺癌背景与流行病学、分期与管理进展(包括新手术技术、靶向治疗与免疫治疗),详述18F-FDG-PET-CT在分期、治疗反应评估和复发检测中的作用,并探讨免疫治疗带来的治疗反应评估挑战及未来靶向诊断与治疗放射性药物的方向。
要点
- 18F-FDG-PET-CT在肺癌分期、治疗反应评估和复发检测中具有重要作用。
- 免疫治疗改善了肺癌患者结局,但给18F-FDG-PET-CT评估治疗反应带来重大挑战与机遇。
- 综述探讨了用于PET/CT成像的有前景的新型靶向诊断放射性药物及靶向治疗放射性药物。
核心结论
- 免疫治疗已改变肺癌管理并改善患者结局,但使用18F-FDG-PET-CT最佳评估肺癌患者治疗反应仍面临重大挑战与机遇。
研究设计与样本
- 综述,覆盖肺癌背景与流行病学、分期与管理进展,包括新手术技术、靶向治疗和免疫治疗。
主要发现
- 过去二十年肺癌分类发生显著变化,涉及多学科输入,并强调免疫组化与分子技术在分类方案中对形态学的贡献日益增加。
- 18F-FDG-PET-CT在肺癌分期、治疗反应评估和复发检测中具有重要作用。
- 综述包含多个基于病例的图示,以例证18F-FDG-PET-CT在不同临床场景中的作用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lung cancer is one of the most common and deadliest forms of cancer worldwide. Over the past two decades, significant changes have occurred in the classification of lung cancer, involving multidisciplinary input and emphasizing the growing contribution of immunohistochemistry and molecular techniques to morphology in the classification scheme. This comprehensive review will cover the background and epidemiology of lung cancer as well as advancements in its staging and management, including discussions of new surgical techniques, targeted therapies, and immunotherapy. The review will detail the role of 18F-FDG-PET-CT in lung cancer, highlighting its importance in staging, treatment response assessment, and recurrence detection. While immunotherapy has transformed lung cancer management and improved patient outcomes, it presents major challenges and opportunities for optimal assessment of treatment response in lung cancer patients using 18F-FDG-PET-CT. This review will also explore future directions, including a discussion of promising new targeted diagnostic radiopharmaceuticals for PET/CT imaging. Additionally, there will be a brief discussion of evolving and exciting treatment options for lung cancer using targeted therapeutic radiopharmaceuticals. Several case-based illustrations are included to exemplify the role of 18F-FDG-PET-CT in various clinical scenarios.
引用
- Cangut B, Akinlusi R, Mohseny A, et al. Evolving Paradigms in Lung Cancer: Latest Trends in Diagnosis, Management, and Radiopharmaceuticals. Semin Nucl Med. 2025. PMID: 40055050. doi:10.1053/j.semnuclmed.2025.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。